These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29158144)

  • 81. Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.
    Stewart A; Roberts JA; Wallis SC; Allworth AM; Legg A; McCarthy KL
    Int J Antimicrob Agents; 2018 Jun; 51(6):941-942. PubMed ID: 29471023
    [No Abstract]   [Full Text] [Related]  

  • 82. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
    Lee AC; Jones AL
    Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
    Ang JY; Abdel-Haq N; Zhu F; Thabit AK; Nicolau DP; Satlin MJ; van Duin D
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5627-30. PubMed ID: 27664282
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
    Tumbarello M; Raffaelli F; Peghin M; Losito AR; Chirico L; Giuliano G; Spanu T; Sartor A; Fiori B; Bassetti M
    Int J Antimicrob Agents; 2020 Apr; 55(4):105900. PubMed ID: 31931150
    [TBL] [Abstract][Full Text] [Related]  

  • 86.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: an interrupted time series analysis.
    Church EC; Mauldin PD; Bosso JA
    Infect Control Hosp Epidemiol; 2011 Apr; 32(4):400-2. PubMed ID: 21460495
    [No Abstract]   [Full Text] [Related]  

  • 88. Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
    Yaita K; Sameshima I; Takeyama H; Matsuyama S; Nagahara C; Hashiguchi R; Moronaga Y; Tottori N; Komatsu M; Oshiro Y; Yamaguchi Y
    Intern Med; 2013; 52(12):1407-12. PubMed ID: 23774557
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.
    Jacqueline C; Roquilly A; Desessard C; Boutoille D; Broquet A; Le Mabecque V; Amador G; Potel G; Caillon J; Asehnoune K
    J Antimicrob Chemother; 2013 Jan; 68(1):177-83. PubMed ID: 22941899
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa.
    Xipell M; Bodro M; Marco F; Losno RA; Cardozo C; Soriano A
    Int J Antimicrob Agents; 2017 Feb; 49(2):266-268. PubMed ID: 27979500
    [No Abstract]   [Full Text] [Related]  

  • 92. Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature.
    Goel N; Bhambhwani V; Ghosh B
    Int Ophthalmol; 2015 Aug; 35(4):599-602. PubMed ID: 26031790
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis.
    Tascini C; Menichetti F; Gemignani G; Palumbo F; Leonildi A; Tedeschi A; Piaggesi A
    Int J Low Extrem Wounds; 2006 Sep; 5(3):213-6. PubMed ID: 16928678
    [TBL] [Abstract][Full Text] [Related]  

  • 94. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?].
    Sinkó J
    Orv Hetil; 2017 Oct; 158(39):1528-1534. PubMed ID: 28942664
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
    Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
    Ronda M; Pérez-Recio S; González Laguna M; Tubau Quintano MF; Llop Talaveron J; Soldevila-Boixader L; Carratalà J; Cuervo G; Padullés A
    J Clin Pharm Ther; 2022 Jul; 47(7):932-939. PubMed ID: 35255527
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
    Krajewski J; Bode-Böger SM; Tröger U; Martens-Lobenhoffer J; Mulrooney T; Mittelstädt H; Russlies M; Kirchner R; Knobloch JK
    Int J Antimicrob Agents; 2014 Oct; 44(4):363-6. PubMed ID: 25182711
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
    Rawlins M; Cheng V; Raby E; Dyer J; Regli A; Ingram P; McWhinney BC; Ungerer JPJ; Roberts JA
    Chemotherapy; 2018; 63(4):203-206. PubMed ID: 30304718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.